- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05070390
A Study of MK-0616 in Participants With Moderate Renal Impairment (MK-0616-007)
May 19, 2023 updated by: Merck Sharp & Dohme LLC
An Open-Label Clinical Study to Evaluate the Pharmacokinetics of MK-0616 Following Administration of a Single Dose to Participants With Moderate Renal Impairment
This purpose of this study is to compare the pharmacokinetics (PK) of a single dose of MK-0616 in participants with moderate renal impairment (RI) to those of healthy matched control participants.
This study is being conducted to assess the impact of moderate renal insufficiency on the PK of MK-0616.
Study Overview
Study Type
Interventional
Enrollment (Actual)
18
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Florida
-
Hallandale Beach, Florida, United States, 33009
- Velocity Clinical Research, Hallandale Beach ( Site 0002)
-
-
Tennessee
-
Knoxville, Tennessee, United States, 37920
- Alliance for Multispecialty Research, LLC ( Site 0001)
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Good health based upon medical history, physical examination, vital signs, laboratory safety tests, and electrocardiograms (ECG) performed before randomization.
- Body mass index (BMI) ≥18 kg/m^2 and ≤40 kg/m^2.
- Male participants must agree to the following during the intervention period and for at least 90 days after the last dose of study intervention: Refrain from donating sperm, PLUS either be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis) and agree to remain abstinent, or use acceptable contraception per study protocol.
- Female participants must be of non-childbearing potential.
- Moderate RI participants: Baseline estimated glomerular filtration rate (eGFR) ≥30 and <60 mL/min/1.73 m^2 based on the Modification of Diet in Renal Disease (MDRD) equation.
- Moderate RI participants: No clinically significant change in renal status at least 1 month prior to dosing and not currently receiving or has not previously been on hemodialysis.
- Healthy Matched Controls: eGFR ≥80 mL/min/1.73 m^2 based on the MDRD equation.
Exclusion Criteria:
- Healthy Matched Controls: history of clinically significant endocrine, GI, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases.
- Mentally or legally incapacitated, has significant emotional problems at the time of prestudy (screening) visit or expected during the conduct of the study or has a history of clinically significant psychiatric disorder of the last 5 years. Participants who have had situational depression may be enrolled in the study at the discretion of the investigator.
- History of cancer, with the exception of adequately treated nonmelanomatous skin carcinoma or carcinoma in situ of the cervix or other malignancies that have been successfully treated with appropriate follow up and therefore unlikely to recur for the duration of the study.
- History of significant multiple and/or severe allergies.
- Positive for hepatitis B surface antigen (HBsAg), hepatitis C antibodies or human immunodeficiency virus (HIV).
- History of major surgery, donated or lost 1 unit of blood (approximately 500 mL) within 4 weeks prior to the prestudy (screening) visit.
- Moderate RI participants: Does not agree to follow the smoking restrictions as defined by the study.
- Healthy Matched Controls: History of smoking and/or has used nicotine or nicotine-containing products (eg, nicotine patch and electronic cigarette) within 3 months of screening.
- Received any nonlive vaccine starting from 14 days prior to study intervention or is scheduled to receive any nonlive vaccine through 30 days following study intervention with the exception of COVID-19 vaccine administration. Study intervention must be given at least 72 hours following or at least 48 hours prior to any COVID-19 vaccination.
- Consumes greater than 3 servings of alcoholic beverages per day.
- Consumes excessive amounts, defined as greater than 6 servings (1 serving is approximately equivalent to 120 mg of caffeine) of coffee, tea, cola, energy drinks, or other caffeinated beverages per day.
- Regular user of cannabis, any illicit drugs or has a history of drug (including alcohol) abuse within approximately 3 months
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Panel A- Moderate RI
Single dose of MK-0616 10 mg
|
10 mg capsule administered orally
|
Experimental: Panel B- Healthy Controls
Single dose of MK-0616 10 mg
|
10 mg capsule administered orally
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-Inf) of MK-0616
Time Frame: Pre-dose and 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 72, 120, 168, 240, and 336 hours post dose
|
Blood for plasma samples will be collected at pre-specified timepoints to determine the AUC0-inf of MK-0616
|
Pre-dose and 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 72, 120, 168, 240, and 336 hours post dose
|
AUC from Time 0 to Last Measurable Concentration (AUClast) of MK-0616
Time Frame: Pre-dose and 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 72, 120, 168, 240, and 336 hours post dose
|
Blood for plasma samples will be collected at pre-specified timepoints to determine the AUClast of MK-0616
|
Pre-dose and 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 72, 120, 168, 240, and 336 hours post dose
|
Maximum Plasma Concentration (Cmax) of MK-0616
Time Frame: Pre-dose and 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 72, 120, 168, 240, and 336 hours post dose
|
Blood for plasma samples will be collected at pre-specified time points to determine the Cmax of MK-0616
|
Pre-dose and 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 72, 120, 168, 240, and 336 hours post dose
|
Time to Maximum Plasma Concentration (Tmax) of MK-0616
Time Frame: Pre-dose and 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 72, 120, 168, 240, and 336 hours post dose
|
Blood for plasma samples will be collected at pre-specified time points to determine the Tmax of MK-0616
|
Pre-dose and 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 72, 120, 168, 240, and 336 hours post dose
|
Apparent Terminal Half-life (t1/2) of MK-0616
Time Frame: Pre-dose and 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 72, 120, 168, 240, and 336 hours post dose
|
Blood for plasma samples will be collected at pre-specified time points to determine the t1/2 of MK-0616
|
Pre-dose and 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 72, 120, 168, 240, and 336 hours post dose
|
Apparent Clearance (CL/F) of MK-0616
Time Frame: Pre-dose and 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 72, 120, 168, 240, and 336 hours post dose
|
Blood for plasma samples will be collected at pre-specified time points to determine the CL/F of MK-0616
|
Pre-dose and 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 72, 120, 168, 240, and 336 hours post dose
|
Apparent Volume of Distribution (Vz/F) of MK-0616
Time Frame: Pre-dose and 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 72, 120, 168, 240, and 336 hours post dose
|
Blood for plasma samples will be collected at pre-specified time points to determine the Vz/F of MK-0616
|
Pre-dose and 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 72, 120, 168, 240, and 336 hours post dose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants Experiencing an Adverse Event (AE)
Time Frame: Up to approximately 14 days
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention
|
Up to approximately 14 days
|
Number of Participants Who Discontinue From the Study due to an AE
Time Frame: Up to approximately 14 days
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention
|
Up to approximately 14 days
|
Amount Recovered in Urine from 0 to 24 hours (Ae0-24) of MK-0616
Time Frame: Pre-dose and and at 0-4, 4-8, 8-12, 12-24, 24-36, and 36-48 hours post dose
|
Urine will be collected at pre-specified time points to determine the Ae0-24 of MK-0616
|
Pre-dose and and at 0-4, 4-8, 8-12, 12-24, 24-36, and 36-48 hours post dose
|
Fraction of Dose Recovered in Urine (Fe) of MK-0616
Time Frame: Pre-dose and and at 0-4, 4-8, 8-12, 12-24, 24-36, and 36-48 hours post dose
|
Urine will be collected at pre-specified time points to determine the Fe of MK-0616
|
Pre-dose and and at 0-4, 4-8, 8-12, 12-24, 24-36, and 36-48 hours post dose
|
Renal Clearance (CLr) of MK-0616
Time Frame: Pre-dose and and at 0-4, 4-8, 8-12, 12-24, 24-36, and 36-48 hours post dose
|
Urine will be collected at pre-specified time points to determine the CLr of MK-0616
|
Pre-dose and and at 0-4, 4-8, 8-12, 12-24, 24-36, and 36-48 hours post dose
|
Maximum Percent Change in Free Proprotein Convertase Subtilisin Kexin 9 (PCSK9) from Baseline
Time Frame: Baseline and up to 336 hours post dose
|
Blood will be collected at pre-specified time points to determine the maximum percent change in free PCSK9 from baseline following administration of a single dose of MK-0616
|
Baseline and up to 336 hours post dose
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Medical Director, Merck Sharp & Dohme LLC
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 16, 2021
Primary Completion (Actual)
May 3, 2023
Study Completion (Actual)
May 3, 2023
Study Registration Dates
First Submitted
October 1, 2021
First Submitted That Met QC Criteria
October 6, 2021
First Posted (Actual)
October 7, 2021
Study Record Updates
Last Update Posted (Actual)
May 23, 2023
Last Update Submitted That Met QC Criteria
May 19, 2023
Last Verified
May 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0616-007
- MK-0616-007 (Other Identifier: Merck)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Moderate Renal Impairment
-
Novartis PharmaceuticalsCompletedMild and Moderate Renal ImpairmentRussian Federation, Germany, Serbia
-
Novartis PharmaceuticalsCompletedMild Moderate | or Severe Renal ImpairmentGermany
-
Daiichi Sankyo Co., Ltd.CompletedHypertension With Moderate Renal ImpairmentJapan
-
Mitsubishi Tanabe Pharma America Inc.CompletedMild and Moderate Hepatic ImpairmentUnited States
-
Boehringer IngelheimCompletedArthroplasty, Replacement | Prevention of Venous Thromboembolism | Moderate Renal Impairment (CrCl 30-50 mL/Min)Austria, Canada, Czechia, Finland, Netherlands, Sweden
-
Agios Pharmaceuticals, Inc.CompletedModerate Hepatic ImpairmentUnited States
-
Merck Sharp & Dohme LLCCompletedModerate Hepatic ImpairmentUnited States
-
KBP BiosciencesCovanceCompletedHealthy | Moderate Hepatic ImpairmentUnited States
-
Tibotec BVBACompletedModerate Hepatic Impairment
-
PfizerRecruitingHealthy Volunteers | Moderate Hepatic Impairment | Severe Hepatic ImpairmentUnited States
Clinical Trials on MK-0616
-
Merck Sharp & Dohme LLCActive, not recruitingHypercholesterolemia | Familial HypercholesterolemiaUnited States, Australia, Brazil, Canada, Chile, Colombia, Czechia, Finland, Hong Kong, Hungary, Israel, Netherlands, New Zealand, Norway, Singapore, Spain, Taiwan
-
Merck Sharp & Dohme LLCCompletedHypercholesterolaemiaUnited States
-
Merck Sharp & Dohme LLCRecruitingHypercholesterolemia | Familial HypercholesterolemiaUnited States, Taiwan, Israel, Argentina, Japan, Korea, Republic of, Turkey, Colombia, China, Mexico, Germany, Italy, South Africa, Spain
-
Merck Sharp & Dohme LLCRecruitingArteriosclerosis | HypercholesterolaemiaUnited States, Taiwan, Canada, Israel, New Zealand, Hong Kong, Argentina, Korea, Republic of, Turkey, Australia, Chile, Brazil, Japan, Colombia, China, United Kingdom, Mexico, Peru
-
Merck Sharp & Dohme LLCCompletedHypercholesterolemia | Familial HypercholesterolemiaUnited States, Germany, Japan, Korea, Republic of, Mexico, Norway, Turkey, United Kingdom
-
Merck Sharp & Dohme LLCCompletedType 2 Diabetes Mellitus
-
Merck Sharp & Dohme LLCTerminated
-
Merck Sharp & Dohme LLCCompletedHypertension | Isolated Systolic Hypertension (ISH)
-
Merck Sharp & Dohme LLCCompleted
-
Merck Sharp & Dohme LLCCompleted